Recruiting NCT07552077

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Phase II Interventional Angiokeratomas

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: PTX-022.
Who it may be relevant to: Registry conditions: Angiokeratomas. Basic parameters: from 6 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: United States
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas

Incidence of Treatment-Emergent Adverse Events [Time frame: 3 months]
Overall Angiokeratoma Investigator Global Assessment (AK-IGA) [Time frame: 3 months]
Overall Patient Global Impression of Change (PGI-C) [Time frame: 3 months]

Any significant concurrent condition that could adversely affect participation
Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022
Patients deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

United States · 4 centers

NCT: NCT07552077 · PALV-12